- Home
- CASI vs IOBT Comparison
CASI vs IOBT Comparison
Compare CASI & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- IOBT
- Stock Information
- Founded
- CASI 1991
- IOBT 2014
- Country
- CASI China
- IOBT Denmark
- Employees
- CASI N/A
- IOBT 78
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- IOBT Health Care
- Exchange
- CASI Nasdaq
- IOBT Nasdaq
- Market Cap
- CASI 35.8M
- IOBT 31.7M
- IPO Year
- CASI 1996
- IOBT 2021
- Fundamental
- Price
- CASI $1.84
- IOBT $0.50
- Analyst Decision
- CASI Strong Buy
- IOBT Hold
- Analyst Count
- CASI 1
- IOBT 3
- Target Price
- CASI $4.00
- IOBT $4.00
- AVG Volume (30 Days)
- CASI 305.0K
- IOBT 4.6M
- Earning Date
- CASI 11-13-2025
- IOBT 11-11-2025
- Dividend Yield
- CASI N/A
- IOBT N/A
- EPS Growth
- CASI N/A
- IOBT N/A
- EPS
- CASI N/A
- IOBT N/A
- Revenue
- CASI $31,564,000.00
- IOBT N/A
- Revenue This Year
- CASI N/A
- IOBT N/A
- Revenue Next Year
- CASI N/A
- IOBT N/A
- P/E Ratio
- CASI N/A
- IOBT N/A
- Revenue Growth
- CASI 36.64
- IOBT N/A
- 52 Week Low
- CASI $1.09
- IOBT $0.32
- 52 Week High
- CASI $7.50
- IOBT $2.79
- Technical
- Relative Strength Index (RSI)
- CASI 51.04
- IOBT 26.96
- Support Level
- CASI $1.77
- IOBT $0.35
- Resistance Level
- CASI $2.08
- IOBT $0.55
- Average True Range (ATR)
- CASI 0.20
- IOBT 0.09
- MACD
- CASI 0.02
- IOBT -0.10
- Stochastic Oscillator
- CASI 71.84
- IOBT 11.78
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.